Teachers Retirement System of The State of Kentucky Buys 1,321 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Teachers Retirement System of The State of Kentucky raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 66,746 shares of the medical research company's stock after purchasing an additional 1,321 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in Thermo Fisher Scientific were worth $34,723,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Barrett & Company Inc. bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $28,000. FPC Investment Advisory Inc. acquired a new position in Thermo Fisher Scientific in the 4th quarter worth $28,000. Pillar Financial Advisors LLC bought a new position in Thermo Fisher Scientific during the 4th quarter worth about $29,000. Missouri Trust & Investment Co bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $29,000. Finally, Endeavor Private Wealth Inc. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $30,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded down $2.64 on Friday, hitting $424.02. The stock had a trading volume of 2,698,284 shares, compared to its average volume of 1,742,311. The stock has a market cap of $160.06 billion, a price-to-earnings ratio of 25.65, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. The business's 50 day moving average is $487.28 and its two-hundred day moving average is $527.66. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a twelve month low of $409.85 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.

Insider Activity

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the transaction, the chief financial officer now directly owns 27,296 shares of the company's stock, valued at $15,984,264.64. The trade was a 26.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,900 shares of company stock worth $13,106,062. Corporate insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. StockNews.com cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Friday. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 target price for the company in a report on Friday, January 10th. Raymond James reiterated an "outperform" rating and issued a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Barclays reduced their price objective on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Finally, Morgan Stanley lifted their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. Five equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $616.95.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.